Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease.
We compared the immunogenicity of 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine to immunization with 23-valent vaccine only in individuals > or = 2 years of age with sickle cell disease. IgG pneumococcal antibody concentrations were higher in the combined schedule group with no increase in side effects observed after immunization with 23-valent vaccine.
Vernacchio
L
L
Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Neufeld
E J
EJ
MacDonald
K
K
Kurth
S
S
Murakami
S
S
Hohne
C
C
King
M
M
Molrine
D
D
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D013296:Streptococcus pneumoniae / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D018074:Vaccines, Conjugate